PAT-DX1/Radiation Combination Improves Brain Cancer Survival
Filed with ASX · · 4 pages · English
Telethon Kids Cancer Centre has completed a new animal study in high grade glioma, finding that PAT-DX1 improves the efficacy of radiation therapy In combination with a therapeutic dose of radiation, PAT-DX1 resulted in significantly prolonged survival compared to radiation alone, with 2 of 10 mice being long term survivors Even below its optimal dose PAT-DX1 as a single agent increased surv
Earlier from Patrys
- Appendix 4C - Quarterly - 30 June 2022
- PAT-DX1 Engineering Run Successfully Completed
- New Mechanism By Which PAT-DX1 May Reduce Cancer Metastasis
- CBCF funding to support deoxymab brain cancer development
- Appendix 4C - Quarterly - 31 March 2022
Later from Patrys
- New Research Grant For Deoxymabs in Metastatic Breast Cancer
- PAT-DX1 From Engineering Run Meets all Specification Tests
- Appendix 4E and 2022 Annual Report
- PAT DX3 Crosses Blood Brain Barrier in Healthy Animals
- Appendix 4C - Quarterly - 30 September 2022
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys